ACRO Biomedical Statistics

Total Valuation

ACRO Biomedical has a market cap or net worth of TWD 4.81 billion. The enterprise value is 4.33 billion.

Market Cap	4.81B
Enterprise Value	4.33B

Important Dates

The last earnings date was Monday, August 11, 2025.

Earnings Date	Aug 11, 2025
Ex-Dividend Date	n/a

Share Statistics

ACRO Biomedical has 61.22 million shares outstanding. The number of shares has increased by 16.17% in one year.

Current Share Class	61.22M
Shares Outstanding	61.22M
Shares Change (YoY)	+16.17%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	17.23%
Owned by Institutions (%)	n/a
Float	43.60M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	108.78
PB Ratio	7.68
P/TBV Ratio	7.76
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-69.72
EV / Sales	97.86
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-58.55

Financial Position

The company has a current ratio of 28.68, with a Debt / Equity ratio of 0.03.

Current Ratio	28.68
Quick Ratio	27.58
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.21
Interest Coverage	-226.06

Financial Efficiency

Return on equity (ROE) is -9.46% and return on invested capital (ROIC) is -5.99%.

Return on Equity (ROE)	-9.46%
Return on Assets (ROA)	-5.89%
Return on Invested Capital (ROIC)	-5.99%
Return on Capital Employed (ROCE)	-10.15%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.06
Inventory Turnover	1.79

Taxes

In the past 12 months, ACRO Biomedical has paid 17,000 in taxes.

Income Tax	17,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +216.73% in the last 52 weeks. The beta is 0.73, so ACRO Biomedical's price volatility has been lower than the market average.

Beta (5Y)	0.73
52-Week Price Change	+216.73%
50-Day Moving Average	53.61
200-Day Moving Average	36.00
Relative Strength Index (RSI)	59.51
Average Volume (20 Days)	1,929,162

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ACRO Biomedical had revenue of TWD 44.23 million and -62.09 million in losses. Loss per share was -1.01.

Revenue	44.23M
Gross Profit	26.19M
Operating Income	-64.65M
Pretax Income	-62.07M
Net Income	-62.09M
EBITDA	-58.18M
EBIT	-64.65M
Loss Per Share	-1.01

Full Income Statement

Balance Sheet

The company has 498.95 million in cash and 15.85 million in debt, giving a net cash position of 483.10 million or 7.89 per share.

Cash & Cash Equivalents	498.95M
Total Debt	15.85M
Net Cash	483.10M
Net Cash Per Share	7.89
Equity (Book Value)	626.28M
Book Value Per Share	10.23
Working Capital	510.92M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -43.38 million and capital expenditures -30.55 million, giving a free cash flow of -73.93 million.

Operating Cash Flow	-43.38M
Capital Expenditures	-30.55M
Free Cash Flow	-73.93M
FCF Per Share	-1.21

Full Cash Flow Statement

Margins

Gross margin is 59.21%, with operating and profit margins of -146.17% and -140.37%.

Gross Margin	59.21%
Operating Margin	-146.17%
Pretax Margin	-140.33%
Profit Margin	-140.37%
EBITDA Margin	-131.54%
EBIT Margin	-146.17%
FCF Margin	n/a

Dividends & Yields

ACRO Biomedical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.17%
Shareholder Yield	n/a
Earnings Yield	-1.29%
FCF Yield	-1.54%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ACRO Biomedical has an Altman Z-Score of 38 and a Piotroski F-Score of 1.

Altman Z-Score	38
Piotroski F-Score	1